AR114998A1 - Compuestos de benzamida - Google Patents

Compuestos de benzamida

Info

Publication number
AR114998A1
AR114998A1 ARP190100053A ARP190100053A AR114998A1 AR 114998 A1 AR114998 A1 AR 114998A1 AR P190100053 A ARP190100053 A AR P190100053A AR P190100053 A ARP190100053 A AR P190100053A AR 114998 A1 AR114998 A1 AR 114998A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
substituted
group
alkyl
haloalkyl
Prior art date
Application number
ARP190100053A
Other languages
English (en)
Inventor
Kevin Duane Bunker
Joseph Robert Pinchman
Peter Qinhua Huang
Rakesh Kumar Sit
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of AR114998A1 publication Critical patent/AR114998A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable de este, que tiene la estructura mostrada a continuación, en donde: R¹ se selecciona del grupo que consiste en hidrógeno, halógeno, un alquilo C₁₋₆ sustituido o no sustituido, un haloalquilo C₁₋₆ sustituido o no sustituido, un cicloalquilo C₃₋₆ sustituido o no sustituido, un alcoxi C₁₋₆ sustituido o no sustituido, una monoalquilamina C₁₋₆ no sustituida y una dialquilamina C₁₋₆ no sustituida, con la condición de que R¹ no sea -CH₂F, -CHF₂ o -CF₃; cada R² se selecciona independientemente del grupo que consiste en halógeno, un alquilo C₁₋₆ sustituido o no sustituido, un haloalquilo C₁₋₆ sustituido o no sustituido y un cicloalquilo C₃₋₆ sustituido o no sustituido; o cuando m es 2 ó 3, cada R² se selecciona independientemente del grupo que consiste en halógeno, un alquilo C₁₋₆ sustituido o no sustituido, un haloalquilo C₁₋₆ sustituido o no sustituido y un cicloalquilo C₃₋₆ sustituido o no sustituido, o dos grupos R² tomados junto con el(los) átomo(s) a los que están unidos forman un cicloalquilo C₃₋₆ sustituido o no sustituido o un heterociclilo de 3 a 6 miembros sustituido o no sustituido; R³ se selecciona del grupo que consiste en, X-R³A, un compuesto de fórmula (2) y un compuesto de fórmula (3); R³A es un heteroarilo de 5 a 10 miembros sustituido o no sustituido; R⁴ se selecciona del grupo que consiste en NO₂, S(O)R⁶, SO₂R⁶, halógeno, ciano y un haloalquilo C₁₋₆ no sustituido; R⁵ se selecciona del grupo que consiste en -X¹-(AIk¹)ₙ-R⁷ y -X²(CHR⁸)-(AIk²)ₚ-X³-R⁹; Alk¹ y Alk² se seleccionan independientemente de un alquileno C₁₋₄ no sustituido y un alquileno C₁₋₄ sustituido con 1, 2 ó 3 sustituyentes seleccionados independientemente de fluoro, cloro, un alquilo C₁₋₃ no sustituido y un haloalquilo C₁₋₆ no sustituido; R⁶ se selecciona del grupo que consiste en un alquilo C₁₋₆ sustituido o no sustituido, un haloalquilo C₁₋₆ sustituido o no sustituido y un cicloalquilo C₃₋₆ sustituido o no sustituido; R⁷ se selecciona de un alcoxi C₁₋₆ sustituido o no sustituido, un cicloalquilo C₃₋₁₀ sustituido o no sustituido, un heterociclilo de 3 a 10 miembros sustituido o no sustituido, hidroxi, amino, un grupo amina monosustituido sustituido o no sustituido, un grupo amina disustituido sustituido o no sustituido, un N-carbamilo sustituido o no sustituido, un C-amido sustituido o no sustituido y un N-amido sustituido o no sustituido; R⁸ se selecciona de un heterociclil(alquilo C₁₋₆) de 3 a 10 miembros sustituido o no sustituido, una di-alquilamina C₁₋₆-(alquilo C₁₋₆) sustituida o no sustituida y una mono-alquilamina C₁₋₆-(alquilo C₁₋₆) sustituida o no sustituida; R⁹ se selecciona de un heteroarilo de 5 a 10 miembros sustituido o no sustituido y un arilo C₆₋₁₀ sustituido o no sustituido; m es 0, 1, 2 ó 3; n y p se seleccionan independientemente de 0 y 1; X¹ y X² son -NH-; y X y X³ se seleccionan independientemente del grupo que consiste en -O-, -S- y -NH-.
ARP190100053A 2018-01-10 2019-01-10 Compuestos de benzamida AR114998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862615857P 2018-01-10 2018-01-10

Publications (1)

Publication Number Publication Date
AR114998A1 true AR114998A1 (es) 2020-11-18

Family

ID=67218673

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP190100050A AR114948A1 (es) 2018-01-10 2019-01-10 Compuestos de benzamida
ARP190100051A AR114949A1 (es) 2018-01-10 2019-01-10 Compuesto de benzamida
ARP190100052A AR114950A1 (es) 2018-01-10 2019-01-10 Compuestos de benzamida
ARP190100053A AR114998A1 (es) 2018-01-10 2019-01-10 Compuestos de benzamida

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP190100050A AR114948A1 (es) 2018-01-10 2019-01-10 Compuestos de benzamida
ARP190100051A AR114949A1 (es) 2018-01-10 2019-01-10 Compuesto de benzamida
ARP190100052A AR114950A1 (es) 2018-01-10 2019-01-10 Compuestos de benzamida

Country Status (15)

Country Link
US (6) US11344546B2 (es)
EP (3) EP3737681A4 (es)
JP (4) JP2021510165A (es)
KR (3) KR20200108302A (es)
CN (5) CN111801320A (es)
AR (4) AR114948A1 (es)
AU (4) AU2019207608B2 (es)
BR (3) BR112020014160A2 (es)
CA (3) CA3087263A1 (es)
IL (3) IL275763A (es)
MX (4) MX2020007014A (es)
RU (2) RU2020120928A (es)
SG (3) SG11202005784YA (es)
TW (5) TW201934538A (es)
WO (4) WO2019139899A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
RS63603B1 (sr) 2017-04-18 2022-10-31 Shanghai Fochon Pharmaceutical Co Ltd Sredstva za indukciju apoptoze
JP2021510165A (ja) 2018-01-10 2021-04-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー ベンズアミド化合物
AR119379A1 (es) * 2019-07-10 2021-12-15 Recurium Ip Holdings Llc Inhibidores de la proteína bcl-2
KR20220034038A (ko) * 2019-07-10 2022-03-17 리커리엄 아이피 홀딩스, 엘엘씨 Bcl-2 억제제의 나노입자 제형
KR20230127372A (ko) 2019-12-06 2023-08-31 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
US20230065577A1 (en) * 2019-12-20 2023-03-02 Recurium Ip Holdings, Llc Combinations
AU2020407068A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
BR112022012283A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
CN115427042A (zh) * 2019-12-20 2022-12-02 里科瑞尔姆Ip控股有限责任公司 组合
WO2021167987A1 (en) * 2020-02-21 2021-08-26 Recurium Ip Holdings, Llc Difluoromethyl iodo compounds and methods
US20230167105A1 (en) * 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
KR20230007360A (ko) * 2020-05-07 2023-01-12 리커리엄 아이피 홀딩스, 엘엘씨 복합제
EP4138837A4 (en) * 2020-05-19 2024-05-22 Recurium IP Holdings, LLC TREATMENT OF AMYLOIDOSIS
WO2022082180A1 (en) * 2020-10-16 2022-04-21 Recurium Ip Holdings, Llc Combinations of bcl-2 inhibitors with chemotherapeutic agents
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途
CN113816889B (zh) * 2021-10-11 2023-08-22 中国药科大学 一类4-磺酰亚胺-1H-吡咯类Mcl-1抑制剂及其抗肿瘤医药用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003096461A (ja) 2001-09-25 2003-04-03 Fuji Photo Film Co Ltd 液晶組成物およびそれを用いた液晶素子
DE10217814A1 (de) 2002-04-22 2003-11-13 Ibfb Pharma Gmbh Neue tricyclische Mercaptane, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
JP4628140B2 (ja) 2005-03-03 2011-02-09 富士フイルム株式会社 セルロースアシレートフィルム、偏光板および液晶表示装置
JP5132550B2 (ja) 2005-05-12 2013-01-30 アボット・ラボラトリーズ アポトーシス促進剤
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
ES2423029T3 (es) 2006-11-15 2013-09-17 Genentech, Inc. Compuestos de arilsulfonamida
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA2671399A1 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
KR101692705B1 (ko) * 2008-12-05 2017-01-04 애브비 인코포레이티드 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN102282128B (zh) 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20190086591A (ko) 2009-05-26 2019-07-22 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
CN102802609A (zh) 2009-06-18 2012-11-28 雅培制药有限公司 稳定的纳米颗粒药物悬浮液
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
IN2012DN01325A (es) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012058392A1 (en) 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2638007A2 (en) 2010-11-11 2013-09-18 Redx Pharma Limited Drug derivatives
CN105664164B (zh) 2010-11-23 2020-05-05 艾伯维巴哈马有限公司 使用选择性的bcl-2抑制剂的治疗方法
US8691184B2 (en) 2011-01-25 2014-04-08 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
ES2819232T3 (es) 2013-01-16 2021-04-15 Univ Michigan Regents Inhibidores de Bcl-2/Bcl-xL y su uso en el tratamiento de cáncer
RS57569B1 (sr) 2013-03-13 2018-10-31 Abbvie Inc Postupci za pripremanje agensa koji uzrokuje apoptozu
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9168257B2 (en) 2013-05-22 2015-10-27 Children's Hospital Medical Center Combination therapy for MDS
NZ714357A (en) 2013-05-24 2018-12-21 Mark Barry Hampton Polycyclic ether compounds and their use in anticancer therapy
CA2917767C (en) 2013-07-12 2022-05-03 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Cystobactamides
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
CN105012318B (zh) 2014-04-17 2020-02-11 沈华浩 磺酰胺类化合物在气道慢性炎症性疾病中的应用
CN104131034B (zh) 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
WO2016025652A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
CN108025006A (zh) 2015-02-06 2018-05-11 尤尼蒂生物技术公司 化合物及在治疗衰老相关病症中的用途
WO2016131100A1 (en) 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
BR112017022553A2 (pt) * 2015-04-20 2018-07-17 Mayo Found Medical Education & Res métodos e materiais para matar células infectadas por hiv
MA44645B1 (fr) 2015-05-26 2019-09-30 Hoffmann La Roche Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
GB201513481D0 (en) 2015-07-30 2015-09-16 Univ Manchester Inhibitor compounds
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN106608895A (zh) 2015-10-21 2017-05-03 苏州国匡医药科技有限公司 一类具有糖环结构的bcl-2选择性抑制剂及其用途
WO2017101851A1 (en) 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
CN106957315B (zh) 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
EP3402485A1 (en) 2016-01-11 2018-11-21 Merrimack Pharmaceuticals, Inc. Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CA3018991A1 (en) 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
AU2017277949B2 (en) 2016-06-09 2023-01-12 Blinkbio, Inc. Silanol based therapeutic payloads
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
CN106749233B (zh) 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
JP2021510165A (ja) 2018-01-10 2021-04-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー ベンズアミド化合物
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
AU2019343044A1 (en) 2018-09-18 2021-03-18 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer

Also Published As

Publication number Publication date
CN118084905A (zh) 2024-05-28
JP2021510163A (ja) 2021-04-15
AR114949A1 (es) 2020-11-11
MX2020007388A (es) 2020-10-12
US20220226314A1 (en) 2022-07-21
SG11202005785XA (en) 2020-07-29
TW201930302A (zh) 2019-08-01
WO2019139902A1 (en) 2019-07-18
US11344546B2 (en) 2022-05-31
CA3087262A1 (en) 2019-07-18
US11318134B2 (en) 2022-05-03
KR20200108302A (ko) 2020-09-17
CN111801327B (zh) 2024-02-09
AU2019207608A1 (en) 2020-07-09
JP2021510165A (ja) 2021-04-15
WO2019139899A8 (en) 2020-07-16
US20240180899A1 (en) 2024-06-06
NZ765825A (en) 2023-12-22
TW201930317A (zh) 2019-08-01
US20200339605A1 (en) 2020-10-29
AR114950A1 (es) 2020-11-11
EP3737672A1 (en) 2020-11-18
AU2024203833A1 (en) 2024-06-27
IL275762A (en) 2020-08-31
BR112020014160A2 (pt) 2020-12-08
US11813260B1 (en) 2023-11-14
MX2023009185A (es) 2023-08-21
MX2020007392A (es) 2020-10-14
CA3087261A1 (en) 2019-07-18
SG11202005784YA (en) 2020-07-29
KR20200108298A (ko) 2020-09-17
US11813259B2 (en) 2023-11-14
EP3737672A4 (en) 2021-09-15
JP2021510376A (ja) 2021-04-22
AU2019207611A1 (en) 2020-07-09
EP3740487A4 (en) 2021-11-10
WO2019139900A1 (en) 2019-07-18
CA3087263A1 (en) 2019-07-18
AU2019207608B2 (en) 2024-03-28
IL275763A (en) 2020-08-31
JP7355741B2 (ja) 2023-10-03
TWI829664B (zh) 2024-01-21
TW202417442A (zh) 2024-05-01
AR114948A1 (es) 2020-11-11
KR20200108301A (ko) 2020-09-17
CN111801327A (zh) 2020-10-20
WO2019139899A1 (en) 2019-07-18
RU2020120929A (ru) 2022-02-25
US11590126B2 (en) 2023-02-28
IL275761A (en) 2020-08-31
US20210009543A1 (en) 2021-01-14
BR112020014151A2 (pt) 2020-12-08
TW201934550A (zh) 2019-09-01
US20200338071A1 (en) 2020-10-29
RU2020120928A (ru) 2022-02-25
CN111788203A (zh) 2020-10-16
BR112020014169A2 (pt) 2020-12-08
MX2020007014A (es) 2020-11-11
EP3737681A4 (en) 2022-01-12
AU2019207616A1 (en) 2020-07-09
EP3740487A1 (en) 2020-11-25
SG11202005985PA (en) 2020-07-29
WO2019139907A1 (en) 2019-07-18
JP2024001052A (ja) 2024-01-09
EP3737681A1 (en) 2020-11-18
RU2020120933A (ru) 2022-02-10
CN118084904A (zh) 2024-05-28
CN111801320A (zh) 2020-10-20
TW201934538A (zh) 2019-09-01

Similar Documents

Publication Publication Date Title
AR114998A1 (es) Compuestos de benzamida
AR114254A1 (es) Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR107840A1 (es) INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR091498A1 (es) DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA
AR117398A1 (es) Inhibidores de la señalización mediada por tirosina cinasa 2
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR108387A1 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
AR108185A1 (es) Amidas terciarias y método para su uso
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR114369A1 (es) Dinucleótidos cíclicos como agentes antineoplásicos
AR119379A1 (es) Inhibidores de la proteína bcl-2
AR123121A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR119378A1 (es) Formulación de nanopartículas del inhibidor de bcl-2

Legal Events

Date Code Title Description
FB Suspension of granting procedure